Alkermes
Tracked across 3 events · 20 articles · First seen Jun 15, 2026 · Last active Sep 16, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Alkermes received Orphan Drug Designations for alixorexton, which provides incentives and market exclusivity, positively impacting its drug development and potential future revenue.
Jun 15, 2026 · 7 articles
Business
Impact: Alkermes reported its Q2 2026 financial results and hosted a conference call. The event is central to the company's quarterly reporting cycle.
Jul 14, 2026 · 6 articles
Business
Alkermes (Nasdaq: ALKS) announced the appointment of Anne C. Whitaker as a new independent director to its Board of Directors. The appointment was announced on Wednesday, September 16, 2026, according to a company press release.…
Impact: Alkermes is the company making the board appointment; the addition of Mike Whitaker strengthens its board with biopharmaceutical commercial and operational expertise. The market reaction was muted, with shares trading nearly flat.
Sep 16, 2026 · 7 articles
90
Alkermes appointed independent director Mike WhitakerAlkermes Appoints Anne...
ERGEN INTELLIGENCE
Track Alkermes live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard